Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41.
View in:
PubMed
subject areas
Animals
Antigens, Neoplasm
Antineoplastic Agents
Cell Line, Tumor
Cell Survival
CTLA-4 Antigen
Humans
Imidazoles
Immunotherapy
Major Histocompatibility Complex
MAP Kinase Kinase Kinases
Melanoma
Mice
Mice, Inbred C57BL
Mice, Transgenic
Oximes
Programmed Cell Death 1 Receptor
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Pyridones
Pyrimidinones
Skin Neoplasms
authors with profiles
Richard Koya